Compare ACNB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | MYGN |
|---|---|---|
| Founded | 1857 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 481.6M |
| IPO Year | 1994 | 1996 |
| Metric | ACNB | MYGN |
|---|---|---|
| Price | $47.25 | $4.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $52.00 | $7.64 |
| AVG Volume (30 Days) | 42.0K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | $191,821,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $13.18 | $6.89 |
| Revenue Next Year | $1.91 | $5.35 |
| P/E Ratio | $13.18 | ★ N/A |
| Revenue Growth | ★ 45.10 | 2.33 |
| 52 Week Low | $35.70 | $3.76 |
| 52 Week High | $53.89 | $8.63 |
| Indicator | ACNB | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 36.52 |
| Support Level | $42.84 | $4.24 |
| Resistance Level | $49.13 | $5.69 |
| Average True Range (ATR) | 1.23 | 0.32 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 67.64 | 2.96 |
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.